Skip to main content
Psych Congress  

Antipsychotic persistence patterns in patients with schizophrenia: polypharmacy vs monotherapy

Authors  
Kathleen F. Villa MS
Kathleen Reilly MA
Maxine Fisher PhD
Keith Isenberg MD
Sponsor  
Roche

Objective: To characterize real-world patterns of persistence in patients with schizophrenia treated with antipsychotic (AP) monotherapy vs AP polypharmacy.


Methods: We examined commercial claims from 01/01/2007 to 04/30/2010 using the HealthCore Integrated Research Database. Patients (N=4156) 13-64 years old with ≥2 claims for schizophrenia and treated with APs (2nd and/or 1st generation) were followed for 1 year. Groups were categorized as: AP monotherapy (1 antipsychotic: 77%) and AP polypharmacy (2+ antipsychotics: 23%). Differences in therapy duration, and proportions of patients discontinuing were analyzed. Regression analyses were used to predict discontinuation before 12 months, and therapy duration.

 
Results: Most patients discontinued AP therapy prior to 1-year follow-up (77% polypharmacy vs 53% monotherapy patients). 50% of polypharmacy patients discontinued AP treatment (1 or more APs) before 3 months vs 17% of monotherapy patients. Mean therapy duration was significantly shorter for polypharmacy than monotherapy patients. 69% of monotherapy patients <26 years old discontinued by 12 months vs 47% of monotherapy patients >45 years. Among polypharmacy patients, 88% of patients <26 years, and 72% of patients >45 years discontinued prior to 1 year. Both age and polypharmacy use were independent predictors of therapy duration and discontinuation by 12 months. In addition, having ≥3 additional psychiatric medications was associated with shorter therapy duration.

 
Conclusion: Persistence with AP therapy is low, especially among younger patients and patients on polypharmacy. Continuance differences by age and type of therapy may be due to differences in disease severity.

Back to Top